44 results about "Gastric emptying" patented technology

The invention discloses a composition for regulating body weight through satiety-sugar control double channels. The composition is prepared from the following components in parts by weight: 5-25 parts of cinnamon extract, 1-20 parts of ganoderma lucidum EGCG composite powder, 10-40 parts of L-arabinose, 5-40 parts of composite fruit and vegetable fiber powder, 5-25 parts of fructus cannabis protein peptide, 1-20 parts of apple polyphenol, 1-20 parts of white kidney bean dietary fiber powder and 1-20 parts of agaricus bisporus powder. The composition is characterized in that digestion and absorption of carbohydrate are inhibited, the swelling ratio larger than or equal to 35 times is achieved through a composite fiber system, gastric emptying is remarkably prolonged, satiety hormones such as GLP-1 are adjusted, and the composition can be used as a non-alternative weight management product and is good in safety.

The invention provides a traditional Chinese medicine composition for improving spleen and stomach health and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 25 to 30 parts of rhizoma dioscoreae, 15 to 20 parts of rhizoma atractylodis macrocephalae, 8 to 15 parts of fructus aurantii, 10 to 15 parts of red dates, 8 to 12 parts of liquorice root, 10 to 15 parts of inulin, 6 to 10 parts of fructus amomi and 5 to 8 parts of cassia twig. The lauric acid modified fenugreek gum (LA-FG) is used as an emulsifier and an immobilized enzyme carrier to construct a water-oil two-phase enzymolysis system, so that the content of effective active ingredients in the traditional Chinese medicine composition, the product stability and the bioavailability are remarkably improved. In addition, the traditional Chinese medicine composition can effectively improve the gastric emptying rate and the small intestine propulsion rate, the level of motilin and anti-inflammatory factors IL-10 is improved, and the effect of improving spleen and stomach health is achieved through multi-target-point synergism. The method successfully breaks through double limitations of a traditional process and an existing scheme, effectively considers volatile oil protection, efficient enzymatic conversion and system stability, and provides a new path for promoting technical upgrading of the traditional Chinese medicine industry.

The utility model relates to an automatic gastric emptying monitoring device of a bionic digestive system, which comprises a rotating disc, the rotating disc is rotationally arranged, the included angle between the center line of the rotating disc and the vertical direction is not zero, and a bionic stomach component is arranged on the rotating disc; the weighing assembly comprises a first container, a measuring instrument and a second container, the measuring instrument and the second container are contained in the first container, the measuring instrument is used for weighing the second container, the second container is communicated with the pylorus of the bionic stomach assembly, the first container comprises a container body and a rotating shaft, the container body is provided with a round hole, and the rotating shaft penetrates through the round hole and is rotationally connected with the container body; the rotating shaft is connected with the rotating disc and extends in the horizontal direction. According to the utility model, the weighing assembly is rotatably arranged on the turntable through the rotating shaft and the round hole, and the weighing assembly is adaptively adjusted to be in a horizontal state by utilizing the gravity of the weighing assembly, so that real-time online monitoring of gastric emptying data is realized, automatic sampling of the bionic gastric assembly is also realized, and the difficulty of sampling work is greatly reduced.

The invention relates to the technical field of traditional Chinese medicine compositions and preparations, in particular to a traditional Chinese medicine composition for treating liver depression and spleen deficiency type chronic gastritis and a preparation method thereof. The traditional Chinese medicine composition is prepared from codonopsis pilosula, rhizoma atractylodis macrocephalae stir-fried with bran, radix bupleuri, stir-fried radix paeoniae alba, pericarpium citri reticulatae, fructus aurantii stir-fried with bran, ginger processed pinellia, radix salviae miltiorrhizae, medicated leaven, stir-fried endothelium corneum gigeriae galli and fingered citron according to The traditional Chinese medicine composition is based on the theory of inhibiting wood and supporting soil in traditional Chinese medicine, and all the components have a synergistic effect and have the effects of soothing the liver, relieving depression, strengthening the spleen and harmonizing the stomach. Animal experiments prove that the traditional Chinese medicine composition provided by the invention can significantly improve the gastric emptying rate and the small intestine propulsion rate of a chronic gastritis model, and can down-regulate the gene expression of gastric mucosa intestinal metaplasia related markers CDX2 and MUC2.

The invention discloses a preparation method of tacrolimus capsules, and relates to the technical field of medicines. The preparation method comprises the following steps: S1, preparing a drug-loaded pellet core; s2, coating and curing a flexible buffer layer, namely curing for 8 hours under the conditions that the temperature is 100 DEG C and the relative humidity is 35%, so that the xanthan gum is in a swelling state; s3, coating with a high-barrier layer; s4, protective controlled release layer coating: preparing a coating solution from the third polymer grafted with the lipophilic bile salt derivative and phospholipid; and S5, capsule filling. Through functional gradient multilayer structure design and fine regulation and control of phospholipid composition and spatial distribution, multiple technical problems of poor chemical stability of tacrolimus, brittle rupture of a coating, burst drug release, dissolution and absorption disorder and release drift caused by individual difference of gastric emptying are synergistically solved; the excellent mechanical strength, stable and controllable release kinetics and obvious solubilization promoting effect of the pellet are realized. The method is clear in technological parameters and suitable for industrial production.

This invention discloses a method and apparatus for modeling the gastric emptying characteristics of compressed dry food. The method includes: obtaining a set of gastrointestinal digestive enzyme concentration ranges; the set of gastrointestinal digestive enzyme concentration ranges includes salivary amylase concentration range, pepsin concentration range, and pancreatic enzyme concentration range; based on the set of gastrointestinal digestive enzyme concentration ranges, performing measurement processing on the compressed dry food to obtain a set of gastric retention rate values; and performing gastric emptying characteristic modeling on the set of gastric retention rate values ​​to obtain a set of gastric emptying models.

The application relates to a composition for treating reflux esophagitis and application thereof. The composition comprises the following components in parts by weight: 2-8 parts of scutellaria baicalensis, 3-7 parts of licorice, 5-10 parts of beeswax and 80-120 parts of vegetable oil. The composition for treating reflux esophagitis contains scutellaria baicalensis, licorice, beeswax and vegetable oil, and through mutual cooperation among the components, the drug prepared from the composition can significantly increase the plasma motilin level of a patient, further increase the pressure of the lower esophageal sphincter, promote gastric emptying and prevent acid reflux, promote the recovery of reflux esophagitis, the esophagus of the patient is obviously improved, and no adverse reaction is found; meanwhile, the content of lipid peroxide can be obviously reduced, the activities of superoxide dismutase and glutathione peroxidase are increased, the esophageal mucosa is protected and treated, the pathological changes of the esophagus are obviously improved, and the treatment effect is excellent.

This invention relates to the field of gastric residual volume detection technology, specifically a Bluetooth transmission device for ultrasound monitoring of gastric residual volume during enteral nutrition for infants and young children. The device includes a main body structure and a transmission device-mounted control system. The control system includes an ultrasound signal acquisition module, a signal processing module, a Bluetooth transmission module, a residual volume calculation module, and a graded alarm module. This invention achieves this by selecting a target frequency band to match the acoustic impedance characteristics of gastric fluid, dynamically tuning the probe's transmission power based on abdominal wall thickness to reduce gas and tissue interference and improve signal accuracy. It corrects signal mapping deviations based on a three-dimensional gastric cavity model, compensates for postural shifts, generates a gastric fluid distribution model to enhance accuracy, dynamically segments data packets and embeds time-series tags to ensure complete transmission and anti-interference capabilities, combines intake rate and gastric emptying curve correction parameters to quantify volume and compensate for errors, improving calculation reliability, and generating graded alarm commands to link with clinical operations.

The invention discloses a two-way positioning release sustained-release pharmaceutical composition and a preparation method thereof, the pharmaceutical composition is a double-layer tablet, and the double-layer tablet comprises an upper-layer tablet and a lower-layer tablet. The upper-layer tablet is a slow-release intragastric positioning release preparation part and contains 1 / 3 marked amount of active ingredients; the lower-layer tablet is a quick-release gastrointestinal tract release preparation part and contains 2 / 3 labeled amount of active ingredients. A new preparation technology and a new dosage form are adopted, the lower-layer tablet in the double-layer tablet can enable the medicine to be rapidly disintegrated in the stomach, the disintegrated medicine forms a particle dispersion, and the particle dispersion can be rapidly emptied by the stomach to enter the intestinal tract, so that the absorption of the medicine is promoted; the upper-layer tablet floats in the stomach after absorbing water, then the medicine is slowly dissolved out, the medicine dissolved out of the preparation can be metabolized into active metabolite OP-1118 in an acid environment in the stomach, then the active metabolite OP-1118 is absorbed through the gastrointestinal tract, and part of the medicine can be absorbed immediately after uniformly and slowly entering the intestinal tract, so that the bioavailability is improved.

The present invention relates to a pharmaceutical composition comprising a polypeptide, and more particularly, to a pharmaceutical composition for preventing or treating obesity, diabetes, or non-alcoholic fatty liver disease. The pharmaceutical composition is safe without any side effects such as vomiting or nausea and has the effects of reducing food intake, enhancing insulin secretion, inhibiting gastric emptying, promoting lipolysis and reducing triglyceride levels.

To provide polypeptide-containing pharmaceutical compositions.SOLUTION: The invention relates to a pharmaceutical composition comprising a polypeptide, more specifically, a pharmaceutical composition for preventing or treating obesity, diabetes or non-alcoholic fatty liver disease. Th pharmaceutical composition is safe without any side effects such as nausea or vomiting with effects of reducing food intake, enhancing insulin secretion, suppressing gastric emptying, promoting lipolysis, and lowering a level of triglycerides. The invention relates to a polypeptide-containing pharmaceutical composition, medical use of the polypeptide-containing pharmaceutical composition, for example, use in treatment or prevention of obesity, diabetes or non-alcoholic fatty liver disease.SELECTED DRAWING: None

The invention belongs to the technical field of pharmaceutical preparations, and provides a probucol sustained-release capsule for reducing the blood fat level and a preparation method thereof, and the probucol sustained-release capsule is prepared by filling a capsule shell with sustained-release pellets, the sustained-release pellet comprises a blank pellet core, a medicine carrying layer, an isolating layer and a sustained-release layer from inside to outside, wherein the medicine carrying layer comprises probucol and an adhesive in a mass ratio of (200-250): (8-12); the slow-release layer is prepared from eudragit RL PO, a plasticizer, a pore-foaming agent and an anti-sticking agent according to the mass ratio of (250 to 300) to (20 to 25) to (20 to 22) to (10 to 18); the pore-foaming agent is prepared from polyethylene glycol 400 and PVP K25 in a mass ratio of (8-12): (3-5). The probucol sustained-release capsule provided by the invention not only has an excellent sustained-release effect, but also enables drug absorption to be less affected by gastric emptying, reduces stimulation to gastrointestinal tracts, and can improve patient compliance.

The present invention relates to Lacticaseibacillus paracasei HP7 with preventive or alleviative efficacy for functional dyspepsia and uses thereof. The composition comprising the Lacticaseibacillus paracasei HP7 strain (accession number: KCTC 13143 BP) of the present invention as an active ingredient was confirmed to increase expression of intestinal tight junction genes, improve gastrointestinal peristalsis and gastric emptying effects, enhances gastric weight and gastric emptying levels associated with gastric emptying, and significantly increase blood hormone levels related to digestive activity, thereby improving dyspepsia.

The application discloses a kind of for skin source fermentation food flavour substance dynamic evaluation method and bionic digestion device.The bionic digestion device includes bionic stomach module and flow path system, bionic stomach module is connected with flow path system;Bionic stomach module is connected with gastric emptying regulation module by flow path system;Gastric emptying regulation module is connected with bionic small intestine module, and the digestion product in bionic stomach module is transported to bionic small intestine module to simulate gastric emptying process;Digestion liquid supplement module is connected with bionic stomach module and bionic small intestine module;Detection module is installed in bionic stomach module, gastric emptying regulation module, bionic small intestine module and flow path system;Sampling module is connected with flow path system, and the side deviating from flow path system is connected with flavour response detection unit.By establishing continuous bionic digestion system, the simulation degree of bionic digestion system to human real digestion process is improved, and the continuous evaluation of flavour change of skin source fermentation food in digestion process is realized.

Described herein are methods and compositions for treatment of diabetes and / or obesity. Bitter oligopeptide molecules formulated for enteric delivery modulate signals involving receptors facing the lumen of the gastrointestinal tract, said signaling related hormones such as glucagon-like peptide-1 (GLP-1) and peptide tyrosine-tyrosine (PYY) that involve inhibition of gastric emptying and appetite. As a novel way to treat diabetes with limited adverse effects the described invention uses body's own endocrine system to treat diabetes, which is an advantage over current therapies that may simply provide disease management without cure or require more radical approaches such as surgical intervention.

The present application relates to a pharmaceutical composition comprising a polypeptide, and more particularly, to a pharmaceutical composition for preventing or treating obesity, diabetes, or non-alcoholic fatty liver disease. The pharmaceutical composition is safe without any side effects such as vomiting or nausea and has an effect of reducing food intake, enhancing insulin secretion, inhibiting gastric emptying, promoting lipolysis, and lowering triglyceride levels.

This invention discloses a linear maltodextrose energy gel and its preparation method, belonging to the field of functional food technology. Using linear maltodextrose with a purity greater than 95% as the basic raw material, the prepared linear maltodextrose energy gel significantly prolongs the exhaustive swimming time of mice by 85.61%, reduces serum lactate by 38.43% and urea nitrogen by 42.67% after exhaustive exercise, and increases liver glycogen by 98.30% and muscle glycogen reserves by 115.63%, effectively alleviating exercise fatigue and reducing bodily damage. The energy gel has a uniform texture, suitable sweetness and viscosity, good palatability when swallowed, and a refreshing aftertaste without any off-flavor. In preparing high-energy-density energy gels, good viscosity and taste can be maintained without adding hydrocolloids. This reduces production costs and simplifies the production process while avoiding the adverse effects of hydrocolloids on gastric emptying speed and sticky texture, resulting in a higher quality energy gel.

The invention discloses a gastric emptying parameter detection system for gastric ultrasonic examination, and belongs to the field of medical images. The gastric emptying parameter detection system for the gastric ultrasonic examination comprises an ultrasonic image acquisition module, an image processing module and a gastric emptying parameter calculation module. The problem that an existing gastric emptying function detection method has limitation is solved, standard section image acquisition can be accurately carried out on the antral sinus part before and after each drinking node through the image acquisition module, and the image processing module extracts and draws gastral cavity boundaries in a time sequence ultrasonic image through an image segmentation algorithm; the gastric emptying parameter calculation module calculates gastric emptying parameters including initial emptying time, emptying curve slope, semi-emptying time, emptying rate at a specific time point and the like based on gastral cavity area data of a time sequence, and the gastric emptying parameter calculation module calculates the gastric emptying parameters including the initial emptying time, the emptying curve slope, the semi-emptying time, the emptying rate at the specific time point and the like based on the gastric cavity area data of the time sequence, so that the accuracy and reliability of gastric emptying area measurement are improved. And objective evaluation of the gastric emptying function can be realized.

Microphysiological platforms are configured for measuring kinetic rates relating to drug absorption. These kinetic rates include GI region-specific kinetic rates of drug absorption. The kinetic rates include bioavailability of the drug over time in various tissues. The kinetic rates include drug permeability in various tissues. The kinetic rates include measurements of microbial transformations that occur. The kinetic rates include measured effects of gastric emptying and transit times. The kinetic rates include measurements of fasting and fed states for various tissues.

The present invention relates to a drug combination for preventing and / or treating obesity. The drug combination is a drug combination of a THR-β agonist and a GLP-1 receptor agonist. The drug combination can achieve a synergistic effect, reduces weight by promoting fat metabolism, reducing fat content, controlling appetite, slowing gastric emptying, increasing satiety, etc., can be used as an effective strategy for solving obesity problems, and has wide prospects for application.

The invention discloses a sugar-free tea flower beverage and a preparation method thereof, and belongs to the technical field of beverage preparation. The sugar-free tea flower beverage prepared by the preparation method provided by the invention is free from cane sugar, but not only has fragrant and sweet smell, but also has fragrant and sweet taste, does not generate heat, and does not cause blood sugar rise and insulin response; the color is bright, the fragrance is rich, the taste is mellow and refreshing, the thirst quenching effect is good, the aftertaste is pure, fragrant and refreshing, the mood is relieved, and the mood is pleasant; the nutritional value is high, the gastric emptying speed of eaters can be slowed down, satiety is generated, and the biscuit is friendly to weight-losing and healthy diet people; the preparation method provided by the invention has the advantages of low requirements on equipment, no use of any chemical reagent, high safety, environmental friendliness, high resource utilization rate and capability of realizing large-scale production.

The invention relates to the technical field of nutrition data analysis, in particular to a nutrition evaluation system based on multi-source data, which comprises a parameter extraction module, a parameter adjustment module, a parameter screening module, a conversion calculation module and an evaluation generation module. According to the method, the individualized gastric emptying rate and amplitude are accurately quantified by acquiring the stomach image in real time and analyzing the volume change of the stomach image at continuous time points, and individualized weight correction is carried out on conventional plasma digestive enzyme activity data by taking the dynamic digestive function parameter as a regulatory factor; then, in combination with instant heart rate and stride frequency data collected by the wearable device, the instant metabolic state of the user is judged, the corrected enzyme activity parameters are screened and matched according to the state, and a personalized nutrition absorption capacity index highly related to the current physiological demand is deduced; and finally, by comparing the dynamic differences of the nutrient conversion amounts at different time points, comprehensive evaluation of the dynamic stability of the nutrient absorption efficiency and the component utilization adaptability is realized.

The present invention provides an apparatus and method that can accurately evaluate the elimination dynamics of preparations, drugs, or food from the stomach. [Solution] A gastric emptying dynamics evaluation device comprising a cylindrical upper part having an inlet A and a drain port A for a test liquid, a plurality of cylindrical fluid actuators having a fluid inlet B connected to the drain port A, a flow path for the fluid flowing in from the fluid inlet B to pass through, and an opening / closing part provided in the flow path for opening and closing the flow path, and a lower part having a drain port B, and control means for controlling the opening and closing of the opening / closing part, wherein the plurality of cylindrical fluid actuators are connected in series, and a method for evaluating gastric emptying dynamics, wherein after introducing a test liquid into the fluid inlet A of the upper part of the evaluation device, the test liquid is moved by opening and closing the opening / closing parts of the plurality of cylindrical fluid actuators in the lower part of the device in phase with each cylindrical fluid actuator, and the test liquid is discharged from the drain port B in the lower part of the device, and the amount or properties of the discharged test liquid are measured.

The application discloses a kind of rich in wheat oligopeptide compressed dry food digestion performance evaluation method and device, the method comprises: using in vitro dynamic human gastrointestinal digestion system, not containing wheat oligopeptide compressed dry food and rich in wheat oligopeptide compressed dry food are respectively simulated digestion processing, respectively measured to obtain first measurement index set and second measurement index set;Each type of measurement index set, including gastric emptying curve, protein digestion rate sequence, amino acid composition value sequence, fat bioavailability sequence;The gastric emptying curve includes several discrete points;The first measurement index set and second measurement index set are preprocessed, and obtain preprocessed index information set;The preprocessed index information set is evaluated and processed, and obtains the digestion performance evaluation value of rich in wheat oligopeptide compressed dry food.

Systems, methods, and devices predict pharmacokinetic parameters following administration of a formulation, such as a medium-chain triglyceride (MCT). The method includes generating training data indicating human metabolism outcomes of the formulation. The training data includes stomach emptying parameters, a digestion rate, an absorption constant, or a conversion rate with a training target variable being ketone concentration or plasma free fatty acid concentration. The method also includes training a physiologically based biopharmaceutics (PBB) model with the training data and using the PBB model to predict, using the patient data, at least one of a target plasma free fatty acid concentration or a target ketone concentration. Furthermore, as part of a parameter sensitivity analysis of the PBB model, the method varies input parameters of the training data against a simulated mean plasma free fatty acid profile or a simulated mean ketone plasma profile.

Described herein are methods and compositions for treatment of diabetes and / or obesity. Bitter oligopeptide molecules formulated for enteric delivery modulate signals involving receptors facing the lumen of the gastrointestinal tract, said signaling related hormones such as glucagon-like peptide-1 (GLP-1) and peptide tyrosine-tyrosine (PYY) that involve inhibition of gastric emptying and appetite. As a novel way to treat diabetes with limited adverse effects the described invention uses body's own endocrine system to treat diabetes, which is an advantage over current therapies that may simply provide disease management without cure or require more radical approaches such as surgical intervention.

The objective of the invention is to provide a critically ill patient grading early activity guidance system based on bedside ultrasound gastric emptying threshold determination, comprising: a gastric emptying monitoring module for acquiring key indexes of gastric emptying through bedside ultrasound; the threshold value judging module is used for judging the gastric emptying state of the patient through a set threshold value algorithm and automatically calculating the proper activity level of the patient; the activity grading module is used for dynamically selecting the most suitable activity level according to the gastric emptying state and the disease severity score (S) of the patient in combination with a specific activity grading rule; the dynamic adjustment module is used for acquiring gastric emptying data of the patient in real time and automatically adjusting the activity level according to activity feedback; the decision support module is used for generating scientific and accurate decision prompts according to the data monitored in real time; and in combination with illness state scores, gastric emptying data and activity feedback, accurate personalized intervention can be realized, and a more scientific and flexible early activity management scheme is provided for critical patients.

Compositions, methods, and kits are described herein for management of postbariatric hypoglycemia or other hypoglycemic disorders characterized by rapid gastric emptying. In certain aspects, such compositions, methods, and kits can effectively slow gastric emptying in a subject in need thereof.

The present invention relates to therapeutic and non-therapeutic methods of using peptide hormone analogs. In particular, the present invention relates to the use of amylin analogs with improved properties, in particular amylin analogs that do not delay gastric emptying.

The present application relates to a kind of local anesthesia intervention preoperative diet planning system, belong to preoperative diet management technical field.The system includes: fluorescence measuring unit is configured to be used to determine the gastric emptying trend line of patient using fluorescence indication method in preoperative planning stage;Diet planning unit is configured to generate the feeding time and feeding category planning of patient according to the gastric emptying trend line of patient and predetermined operation time;Blood glucose detection unit is configured to monitor the blood glucose of patient in real time.Optimally, diet planning unit is further configured to individualize revision the gastric emptying rate of patient according to the real-time monitoring value of blood glucose of patient, and adjust the feeding time and feeding category planning of patient according to the gastric emptying rate after revision.